[Selpercatinib (thyroid cancer) - Benefit assessment according to §35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004349
Original Title: Selpercatinib (RET-mutiertes medullaeres Schilddruesenkarzinom, Erstlinie)
Project Status: Completed
Year Published: 2022
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Thyroid Neoplasms
  • Pyrazoles
  • Pyridines
  • Selpercatinib
  • Thyroid Neoplasms
  • Adolescent
  • Adult
  • Benefit Assessment
  • NCT03157128
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.